Contract research and manufacturing services firm Syngene International Ltd on Thursday (October 23) has confirmed the expansion of its biologics facility with the addition of new antibody-drug conjugate (ADC) bioconjugation capabilities. The company plans to provide fully integrated, end-to-end services for ADCs, covering stages from discovery through GMP manufacturing.
The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and GMP bioconjugation at a single site. This expansion is designed to complement Syngene’s existing commercial capabilities in payload and linker manufacturing.
Also Read: Syngene International acquires first US biologics facility in the USA
The company clarified that this investment in bioconjugation capabilities is part of the ordinary course of business. Syngene stated that the expansion will support its ongoing efforts in biologics development and enhance integrated service offerings for ADCs.
Syngene International’s revenue for the quarter increased by 10.7% from last year to ₹874.5 crore, which was higher than the estimates of ₹853.1 crore by Kotak. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at ₹206.4 crore from ₹169.8 crore. The numbers were better than the Kotak estimate of ₹191.9 crore.
EBITDA margin for the quarter expanded by 210 basis points from the year-ago quarter to 23.6%, which was also higher than the 22.5% estimate. However, the margin figure narrowed from the March quarter figure of 33.8%. Syngene’s revenue and EBITDA are also lower by 14.1% and 40% respectively, on a sequential basis.
Also Read: Syngene’s Bengaluru unit passes US FDA test with VAI classification
Shares of Syngene International Ltd ended at ₹661.10, up by ₹19.25, or 3.00%, on the BSE.
